Exagen Releases Q1 2026 Financial Results – Alphastreet

AlphaStreet Newsdesk powered by AlphaStreet Intelligence

Exagen Inc. (XGN) reported Q1 2026 basic and diluted loss of $0.17 per share, a narrower loss than the -$0.24 estimate (29.2% narrower). Year-over-year, the per-share loss narrowed to $0.17 from $0.20 in Q1 2025, a 15.0% improvement.

Also Read

Circle raises $222 million from BlackRock, Apollo and others in Arc token presale valued at $3 billion

Earnings call transcript: Orix Corp Q4 2026 sees record profits, stock surges

U.S. stock futures fall, oil surges as Trump calls Iran’s latest offer to end war ‘totally unacceptable’

Plugin developed by ProSEOBlogger. Get free gpl themes.

The company generated $17.3M in revenue for the quarter. Revenue was up 12.0% year-over-year.

Exagen Inc. is a Diagnostics & Research company. AVISE CTD test volume was +10.0% for the quarter. The company operated $21.5M in cash and cash equivalents at quarter end. The company posted a net loss of $4.0M for the quarter.

Revenue guidance for the full year was set at $70.0M to $73.0M. Wall Street consensus stands at 7 buy, 1 hold, 0 sell.

A detailed analysis of Exagen Inc.’s quarter follows shortly on AlphaStreet.

This content is for informational purposes only and should not be considered investment advice. AlphaStreet Intelligence analyzes financial data using AI to deliver fast and accurate market information. Human editors verify content.